NEW YORK – Tempus AI said on Tuesday that it has acquired clinical trial patient matching company Deep 6 AI for an undisclosed amount.

纽约——Tempus AI 周二表示，已收购临床试验患者匹配公司 Deep 6 AI，但未透露具体金额。

Deep 6 AI uses artificial intelligence-based software to match patients with clinical trials by mining real-time structured and unstructured electronic medical record data from multiple sources, including academic medical centers, National Cancer Institute-designated cancer centers, and NCI community oncology research programs.

Deep 6 AI 使用基于人工智能的软件，通过挖掘来自多个来源的实时结构化和非结构化电子医疗记录数据，将患者与临床试验进行匹配，这些来源包括学术医疗中心、国家癌症研究所指定的癌症中心以及NCI社区肿瘤研究计划。

The firm's research ecosystem includes more than 45 healthcare organizations and life sciences companies..

该公司研究生态系统包括 45 家以上的医疗组织和生命科学公司。

Structured data includes ICD-10 codes and demographic info like age and gender, while unstructured data includes physician notes, pathology reports, and laboratory results, according to Deep 6 AI's website. The company's software also returns partial results, showing which patients could qualify but are possibly missing a key lab result..

根据Deep 6 AI网站的介绍，结构化数据包括ICD-10代码和年龄、性别等人口统计信息，而非结构化数据则包括医生笔记、病理报告和实验室结果。该公司的软件还会返回部分匹配结果，显示哪些患者可能符合条件，但可能缺少某个关键的实验室结果。

Deep 6 AI,founded in 2016 and based in Pasadena, California,

Deep 6 AI，成立于2016年，总部位于加利福尼亚州帕萨迪纳，

previously partnered

以前的合作伙伴关系

with Genomenon in order to gain insights about conditions like cancer, Parkinson's disease, and Wilson's disease.

与Genomenon合作，以获取有关癌症、帕金森病和威尔逊病等疾病的信息。

'Deep 6's impressive integration infrastructure is well-suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimized care for their patients,' Tempus CEO and Founder Eric Lefkofsky said in a statement. 'This acquisition broadens our reach, adding even more providers to our platform, and enhances our ability to deploy critical applications like Next, which helps physicians close care gaps, and Time, which helps patients find potentially life-saving clinical trials.'.

“Deep 6 强大的集成基础设施非常适合补充我们的连接性工作，这是我们支持医生为患者提供优化护理能力的核心，”Tempus 首席执行官兼创始人 Eric Lefkofsky 在一份声明中表示。“此次收购扩大了我们的覆盖范围，将更多医疗服务提供者加入我们的平台，并增强了我们部署关键应用程序的能力，例如帮助医生弥合护理差距的 Next，以及帮助患者找到可能挽救生命的临床试验的 Time。”

Tempus' Next is an AI-based application that provides insights from multimodal, longitudinal patient data including medical imaging data, EMR data, laboratory results, pathology reports, and clinician notes. The Next application is available for oncology and cardiology and is intended to identify and minimize care gaps..

Tempus的Next是一款基于人工智能的应用程序，提供来自多模态、纵向患者数据的洞察，包括医学影像数据、电子病历数据、实验室结果、病理报告和临床医生笔记。Next应用程序适用于肿瘤学和心脏病学，旨在识别并缩小诊疗差距。

The firm's Time Trial Program is a network that supports rapid patient identification, site activation, and enrollment for certain precision medicine clinical trials. The company uses proprietary trial matching software and methods to identify relevant clinical trials personalized to each patient's molecular and clinical data, according to Tempus' website..

该公司的时间试验计划是一个网络，支持对某些精准医疗临床试验的快速患者识别、站点激活和入组。据Tempus网站介绍，该公司使用专有的试验匹配软件和方法，根据每位患者的分子和临床数据，识别个性化的相关临床试验。